Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Tianqing, Chu"'
Autor:
Bo Zhang, Hongyu Liu, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Tianqing Chu, Huimin Wang, Liwen Xiong, Wei Zhang, Xueyan Zhang, Bo Yan, Jiajun Teng, Weimin Wang, Hao Bai, Rong Qiao, Lei Cheng, Yanbin Kuang, Ruiying Zhao, Hua Zhong, Baohui Han
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) represents a major unmet medical need in non-small cell lung cancer (NSCLC) patients. Vascular endothelial growth factor (VEGF) inhibition may reverse a suppressive microenvironmen
Externí odkaz:
https://doaj.org/article/fd0c3fa6cd7f420a97190e5951f015d2
Autor:
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 419-426 (2024)
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and
Externí odkaz:
https://doaj.org/article/5593cfcf22cf4de189ad661dbe843899
Autor:
Jun Lu, Ying Li, Wei Zhang, Hua Zhong, Fang Hu, Liang Zheng, Xiaohua Yang, Lin Huang, Xueyan Zhang, Tianqing Chu, Baohui Han, Yinchen Shen, Wei Nie, Jianlin Xu, Shuyuan Wang, Runbo Zhong, Xiaoxuan Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment
Externí odkaz:
https://doaj.org/article/b9a445ffb44c4e5997bab417d9a49d00
Autor:
Dingzhi Huang, Gen Lin, Qian Chu, Yi Hu, Jun Wang, Zhijie Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Fengqiao Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 14, Iss 34, Pp 3421-3429 (2023)
Abstract Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clini
Externí odkaz:
https://doaj.org/article/bdd49d5369d24d70bad9a053f8310938
Autor:
Bo Zhang, Hua Zhong, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Weimin Wang, Tianqing Chu, Liwen Xiong, Wei Zhang, Huimin Wang, Xueyan Zhang, Baohui Han
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 12, Pp 1361-1367 (2023)
Abstract Introduction Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical
Externí odkaz:
https://doaj.org/article/a5f8528abb824329a4d37c54d296c13e
Autor:
Jiaqi Li, Mengqing Xie, Ruiying Zhao, Huiping Qiang, Qing Chang, Jialin Qian, Haijiao Lu, Yinchen Shen, Yuchen Han, Chunxia Su, Tianqing Chu
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundFor patients with EGFR/HER2 exon20 insertions, platinum-containing double-drug chemotherapy is still the standard treatment method. First-generation TKIs have almost no therapeutic activity against EGFR exon 20 insertions. The efficacy of s
Externí odkaz:
https://doaj.org/article/37ef7cd262a543e8b47b55aa066a2869
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Background The heterogeneity of lung adenocarcinoma (LUAD) plays a vital role in determining the development of cancer and therapeutic sensitivity and significantly hinders the clinical treatment of LUAD.Objective To elucidate the cellular compositio
Externí odkaz:
https://doaj.org/article/18f9224f03494d32b35710dd002a2421
Autor:
Yulu WANG, Tianqing CHU
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 2, Pp 135-147 (2023)
Epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) is one of the earliest driver gene activation mutations in non-small cell lung cancer (NSCLC). However, due to the unique structure of protein variation caused by this mutation, most p
Externí odkaz:
https://doaj.org/article/62d4ea0a84434f65a06a298c23f061f1
Autor:
Jing Wang, Jie Liu, Yan Zhang, Hua Zhong, Xinmin Yu, Lijuan Chen, Xueyan Zhang, Panwen Tian, Tianqing Chu, Qisen Guo, Zhuang Yu, Yalun Li, Yan Guan, Xun Shi, Yanqiu Zhao, Baohui Han
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Treatment options are limited for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after treatment failure with EGFR tyrosine kinase inhibitors (TKIs). This multicenter open-label, phase II study aims to e
Externí odkaz:
https://doaj.org/article/f10d44306445447cbd0cb29eaf0859aa
Autor:
Jun Lu, Jun Wu, Yuqing Lou, Qin Shi, Jun Xu, Lele Zhang, Wei Nie, Jie Qian, Yanan Wang, Yanwei Zhang, Jing Jiao, Xueyan Zhang, Wei Zhang, Huimin Wang, Tianqing Chu, Hua Zhong, Baohui Han
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-12 (2022)
Abstract Background Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for
Externí odkaz:
https://doaj.org/article/d77f7fe4c0a64902afd728eb1320535b